On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of its 4.950% notes due September 19, 2029. The company intends to use the net proceeds from this issuance, combined with existing cash on hand, to repay $500 million in outstanding principal of its 4.650% notes maturing on September 9, 2026. This refinancing activity involves significant debt restructuring and capital management. Illumina operates in the life sciences industry, specializing in genomic sequencing technologies.

Illumina, Inc. entered into a new $1,000 million senior unsecured five-year revolving credit facility on August 13, 2026, replacing its existing agreement dated January 4, 2023. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit, with an option to increase commitments or add term loans up to $500 million subject to lender consent. Interest rates are variable based on the SOFR or alternate base rate plus an applicable margin tied to the company's debt rating. The facility matures on August 13, 2031, with three one-year extension options, and contains standard financial covenants including a maximum total leverage ratio. No borrowings were outstanding as of the filing date. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.

On August 10, 2026, Illumina entered into an underwriting agreement to issue and sell $300 million in aggregate principal amount of its 4.950% notes due 2029. The offering is expected to close on August 17, 2026, subject to customary conditions. Illumina intends to use the net proceeds from this transaction, combined with existing cash reserves, to repay its outstanding 4.650% notes maturing on September 9, 2026. This debt refinancing activity is a significant capital structure event that alters the company's near-term liability profile and interest obligations. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.

Illumina, Inc. filed a Form 8-K to announce the settlement and proposed dismissal of litigation captioned Icahn Partners LP, et al., v. Francis DeSouza, et al., arising from its approximately $8 billion acquisition of GRAIL, Inc. The parties entered into a Release Agreement on August 21, 2025, providing for mutual releases without any monetary payment by either side. The action will be dismissed with prejudice as to the plaintiffs only, while remaining without prejudice to other stockholders and three pending derivative actions. Defendants continue to deny all claims of wrongdoing or liability. A court hearing on the proposed dismissal is scheduled for November 2, 2026. Illumina, Inc. operates in the life sciences industry, specializing in DNA sequencing and analysis technologies.

Illumina, Inc. reported second quarter fiscal year 2026 financial results on July 30, 2026, for the period ended June 28, 2026. The company generated $1.16 billion in revenue, representing a 9.5% increase from the prior year and an 8.1% organic growth rate excluding currency, acquisitions, and China impacts. GAAP diluted earnings per share were $1.35, while non-GAAP diluted EPS reached $1.31. Illumina raised its full-year fiscal 2026 revenue guidance to a range of $4.60-$4.64 billion from the previous estimate of $4.52-$4.62 billion and increased non-GAAP diluted EPS guidance to $5.30-$5.40 from $5.15-$5.30. The company operates in the genomics industry, providing DNA sequencing and array-based technologies for research, clinical, and applied markets.

Illumina, Inc. increased its Board of Directors from nine to ten members by appointing Daniel M. Skovronsky, M.D., Ph.D., to the Board, effective immediately. Dr. Skovronsky is an independent director who will stand for election at the 2027 annual meeting of stockholders. Illumina, Inc. is a biotechnology company that provides genomic sequencing technology and sequencing-based information.